ALK B Overview
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr.2,882.00|
|52 Week High||kr.1,965.00|
|52 Week Low||kr.3,310.00|
|1 Month Change||-0.35%|
|3 Month Change||-2.37%|
|1 Year Change||33.55%|
|3 Year Change||171.89%|
|5 Year Change||218.10%|
|Change since IPO||321.96%|
Recent News & Updates
ALK-Abelló (CPH:ALK B) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)
Today we will run through one way of estimating the intrinsic value of ALK-Abelló A/S ( CPH:ALK B ) by taking the...
|ALK B||DK Pharmaceuticals||DK Market|
Return vs Industry: ALK B exceeded the Danish Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: ALK B exceeded the Danish Market which returned 20% over the past year.
|ALK B volatility|
|ALK B Beta||0.33|
Stable Share Price: ALK B is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ALK B's weekly volatility (5%) has been stable over the past year.
About the Company
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. Its products include GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma.
ALK-Abelló Fundamentals Summary
|ALK B fundamental statistics|
Is ALK B overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALK B income statement (TTM)|
|Cost of Revenue||kr.1.49b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 11, 2021
|Earnings per share (EPS)||5.01|
|Net Profit Margin||1.51%|
How did ALK B perform over the long term?See historical performance and comparison
Is ALK-Abelló undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ALK B (DKK2882) is trading above our estimate of fair value (DKK2847.36)
Significantly Below Fair Value: ALK B is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ALK B is poor value based on its PE Ratio (575.2x) compared to the European Pharmaceuticals industry average (25.8x).
PE vs Market: ALK B is poor value based on its PE Ratio (575.2x) compared to the Danish market (15.8x).
Price to Earnings Growth Ratio
PEG Ratio: ALK B is poor value based on its PEG Ratio (12.1x)
Price to Book Ratio
PB vs Industry: ALK B is overvalued based on its PB Ratio (9.7x) compared to the XE Pharmaceuticals industry average (3.4x).
How is ALK-Abelló forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALK B's forecast earnings growth (47.7% per year) is above the savings rate (0.1%).
Earnings vs Market: ALK B's earnings (47.7% per year) are forecast to grow faster than the Danish market (8.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ALK B's revenue (11.2% per year) is forecast to grow faster than the Danish market (7.4% per year).
High Growth Revenue: ALK B's revenue (11.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALK B's Return on Equity is forecast to be low in 3 years time (13.8%).
How has ALK-Abelló performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALK B has a large one-off loss of DKK39.0M impacting its June 30 2021 financial results.
Growing Profit Margin: ALK B's current net profit margins (1.5%) are higher than last year (1.5%).
Past Earnings Growth Analysis
Earnings Trend: ALK B's earnings have declined by 33.6% per year over the past 5 years.
Accelerating Growth: ALK B's earnings growth over the past year (12.2%) exceeds its 5-year average (-33.6% per year).
Earnings vs Industry: ALK B earnings growth over the past year (12.2%) exceeded the Pharmaceuticals industry 10.2%.
Return on Equity
High ROE: ALK B's Return on Equity (1.7%) is considered low.
How is ALK-Abelló's financial position?
Financial Position Analysis
Short Term Liabilities: ALK B's short term assets (DKK2.3B) exceed its short term liabilities (DKK1.4B).
Long Term Liabilities: ALK B's short term assets (DKK2.3B) exceed its long term liabilities (DKK934.0M).
Debt to Equity History and Analysis
Debt Level: ALK B's debt to equity ratio (16.8%) is considered satisfactory.
Reducing Debt: ALK B's debt to equity ratio has reduced from 22.3% to 16.8% over the past 5 years.
Debt Coverage: ALK B's debt is well covered by operating cash flow (65.4%).
Interest Coverage: ALK B earns more interest than it pays, so coverage of interest payments is not a concern.
What is ALK-Abelló current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALK B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALK B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALK B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALK B's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: ALK B is not paying a notable dividend for the Danish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALK B's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Carsten Hellmann (57 yo)
Mr. Carsten Hellmann has been the Chief Executive Officer and President at ALK-Abelló A/S since May 17, 2016. Mr. Hellmann serves as the Chief Executive Officer at Merial Inc., Boehringer Ingelheim Animal...
Experienced Management: ALK B's management team is considered experienced (4.6 years average tenure).
Experienced Board: ALK B's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ALK-Abelló A/S's employee growth, exchange listings and data sources
- Name: ALK-Abelló A/S
- Ticker: ALK B
- Exchange: CPSE
- Founded: 1923
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr.31.635b
- Shares outstanding: 10.98m
- Website: https://www.alk.net
Number of Employees
- ALK-Abelló A/S
- Boge Alle 6-8
- Capital Region of Denmark
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/14 21:21|
|End of Day Share Price||2021/10/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.